Becton, Dickinson and Co. | BDX - Selling And Administration Expenses

Stock Price
152.14
Daily Change
-2.71 -1.75%
Monthly
-3.87%
Yearly
-25.81%
Q2 Forecast
155.05

Becton, Dickinson and Co. reported $1.39B in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Abbott USD 3.27B 138M Mar/2026
Agilent USD 476M 48M Dec/2025
Align Technology USD 441.68M 23.88M Dec/2025
AngioDynamics USD 36.57M 3.79M Sep/2025
Avanos Medical USD 78.8M 1.2M Dec/2025
Baxter International USD 761M 53M Dec/2025
Becton, Dickinson and Co. USD 1.39B 27M Dec/2025
Bio-Rad Laboratories USD 206.8M 900K Sep/2025
Boston Scientific USD 1.83B 93M Dec/2025
Cooper Companies USD 373.1M 46.1M Dec/2025
Danaher USD 1.86B 166M Mar/2026
Dentsply International USD 383M 28M Dec/2025
Dexcom USD 299.9M 31.5M Dec/2025
Edwards Lifesciences USD 522.2M 80.7M Mar/2026
Globus Medical USD 318.48M 4.88M Dec/2025
Insulet USD 331.4M 16.2M Dec/2025
Integra LifeSciences USD 156.45M 12.6M Dec/2025
Intuitive Surgical USD 613.3M 73.8M Mar/2026
J&J USD 6.03B 719M Mar/2026
Masimo USD 128M 11.6M Dec/2025
Medtronic 2.97B 159M Sep/2025
Solventum Corp USD 759M 15M Dec/2025
Stryker USD 2.14B 150M Dec/2025
Tandem Diabetes Care USD 99.86M 5.34M Dec/2025
Teleflex USD 222.37M 59.4M Dec/2025
Terumo JPY 105.26B 7.38B Dec/2025
Thermo Fisher Scientific USD 1.8B 179M Mar/2026
Zimmer Biomet Holdings USD 855.7M 44.3M Dec/2025